The Rockefeller University

Chad Euler

Vincent A Fischetti

Jonathan Schmitz

Daniel Gilmer

Anu Daniel

Assaf Raz

The present description relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistantand VISA.

Chimeric bacteriophage lysin with activity againstbacteria

The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, includingand, and related conditions. The invention provides compositions and methods incorporating and utilizingderived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

bacteriophage lysins for detection and treatment of gram positive bacteria

lysins for detection and treatment of gram positive bacteria

The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant(MRSA) and vancomycin intermediate(VISA).

Chimeric bacteriophage lysin with activity against staphylococci bacteria

The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistantand VISA.

[object Object]

The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, includingandand related conditions. The invention provides compositions and methods incorporating and utilizingderived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.

The present disclosure relates to chimeric bacteriophage lysins useful for the identification and/or reduction of staphylococcal populations. For example, a chimeric bacteriophage lysin was engineered and shown to effectively kill all strains of staphylococci tested including antibiotic resistant methicillin-resistant(MRSA) and vancomycin-resistant(VISA).

Growing community of inventors

New York, NY, United States of America

Chad Euler